US Patent

US11795204 — Glucagon analogues

Method of Use · Assigned to Zealand Pharma AS · Expires 2034-01-06 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects stable glucagon analogues suitable for use in a liquid formulation.

USPTO Abstract

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Drugs covered by this patent

dasiglucagon-hydrochloride (DASIGLUCAGON HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3752`	—	dasiglucagon-hydrochloride
`U-3752`	—	dasiglucagon-hydrochloride

Patent Metadata

Patent number: US11795204
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-06
Drug substance claim: No
Drug product claim: No
Assignee: Zealand Pharma AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.